With Expert’Biome™, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry. These services include strains research and development, bioprocesses scaling, drug manufacturing, and […]
At the Microbiome Times Partnering Forum, Arno Bouwens, R&D Director at Perseus Biomics, took to the stage to present their technology, DynaMAP (Dynamic Microbiome Abundance Profiling), for high-resolution microbiome analysis. His talk, titled “DynaMAP – […]
At the Microbiome Times Partnering Forum, Massimo Marzorati, CEO of ProDigest, presents “The Selection of a Pre-Clinical Model is Driven by the Specific Research Question”. A talk highlighting the company’s expertise in simulating the gastrointestinal […]
The Mediterranean diet is regarded as the most beneficial diet from a mental health perspective. The benefits of such a diet are mediated significantly through the brain- gut-microbiota axis. Abnormalities in this axis have been described in the most […]
The majority of the gut microbiota is unculturable using standard laboratory techniques, which has been well-documented since the advent of next generation sequencing in microbiome research. This limitation makes it difficult to characterise the phenotype […]
With bacterial strains of the same species exhibiting remarkably different characteristics, it is vital biotic developers accurately characterise what strains are present in their product. This enables developers to maximise the biotics’ therapeutic potential, provide […]
Scientists have developed a breakthrough method to track diet using stool metagenomic data. Developed by researchers at the Institute for Systems Biology (ISB), the new method, called MEDI (Metagenomic Estimation of Dietary Intake), detects food-derived […]
In early January MaaT Pharma made waves in the pharma world with the announcement of positive topline results for their phase 3 trial of MaaT013 in acute Graft-versus-Host Disease. With robust efficacy and safety data, […]
MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage clinical-stage biotechnology company leading the development of Microbiome Ecosystem Therapies TM (MET) to improve survival in cancer patients through modulation of the immune system, today announced topline results from […]
Following the announcement of Lallemand’s new R&D laboratories in France, Microbiome Times caught up with Sylvie Binda, VP of R&D to discuss the company’s goals and objectives. Can you elaborate on how the new laboratories […]
Eczema and Atopic Dermatitis (AD) is thought to affect as many as 10% of adults worldwide and represents a debilitating condition for many.1 It can result in a lower quality of life, and reports link […]